TOL2506

DRUG2 trials

Sponsors

Tolmar Inc.

Conditions

Breast Cancer

Phase 3

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Active, not recruitingNCT04906395

Tolmar Inc.Breast Cancer

Start: 2021-07-01End: 2026-04-30Target: 250Updated: 2026-01-13

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Enrolling by invitationNCT05645536

Tolmar Inc.Breast Cancer

Start: 2022-12-28End: 2028-06-30Target: 250Updated: 2026-01-12

Related Papers

Abstract OT3-04-01: A Phase 3 study evaluating ovarian suppression following three-month leuprolide acetate in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA)

Cancer Research2023-03-01

A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).

Journal of Clinical Oncology2022-06-011 citations